Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients
Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Xi Jin, phD
- Phone Number: 0086-571-87266532
- Email: jxfl007@hotmail.com
Study Locations
-
-
Zhejaing
-
Hangzhou, Zhejaing, China, 310003
- Recruiting
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
Sub-Investigator:
- Yi da Yang, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients should be diagnosed with chronic hepatitis B infection and hepatic steatosis
CHB infection
- HBV-DNA ≥ 1×105 copies/ml;
- HBeAg positive ;
- ALT between the 2-10 times of the upper limit level
- hepatic steatosis According to the "Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary", with test of CT scan or B ultrasound and confirmation of liver biopsy(in portion of patients)
Exclusion Criteria:
- those receiving antiviral treatment before the study
- those on hepatoxic drug treatment,
- those consuming alcohol regularly or excessively,
- those diagnosed of cirrhosis, anti-HCV or anti-Delta positive patients,
- those diagnosed as having autoimmune or other metabolic liver diseases
- those have wilson's disease, PBC, PSC, IBD and other diseases that may influence the process and effect of therapy
- those who are pregnant, have mental disorder and were received anti-viral treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: control group
patients only with chronic hepatitis B
|
entecavir 0.5 mg qd for 12 months
|
|
Active Comparator: model group
patients with chronic hepatitis B and hepatic steatosis
|
entecavir 0.5 mg qd for 12 months
|
|
Experimental: Essentiale group
patients with chronic hepatitis B and hepatic steatosis
|
entecavir 0.5 mg qd for 12 months,Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
|
|
Experimental: treatment group 2
patients with chronic hepatitis B and hepatic steatosis
|
entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in the anti-viral effect of entecavir among CHB patients and CHB + hepatic steatosis patients who received different drugs
Time Frame: 12 months
|
The common measurement includes serum biochemistry markers (ALT, AST, GGT, CRP, PT, APTT, AMA, UA, Chol, TG, TB, DB, ALP, fasting glucose, insulin, et al), virus markers (HBs-Ag, Hbe-Ag, anti-HBc-Ab, HBV genotype, HBV- DNA copy, YMDD variation, et al), Liver CT scan or ultrasound (steatosis degree and fibrosis and changes in the histological features of liver biopsy(steatosis degree, inflammation and fibrosis).
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in the sustained response rate to entecavir among CHB patients and CHB + hepatic steatosis patients who received different drugs and obtained anti-virus effect after 1 year treatment.
Time Frame: 15 months
|
The common measurement includes serum biochemistry markers (ALT, AST, GGT, CRP, PT, APTT, AMA, UA, Chol, TG, TB, DB, ALP, fasting glucose, insulin, et al), virus markers (HBs-Ag, Hbe-Ag, anti-HBc-Ab, HBV genotype, HBV- DNA copy, YMDD variation, et al), Liver CT scan or ultrasound (steatosis degree and fibrosis).
|
15 months
|
|
Differences in the anti-viral effect of entecavir among CHB patients and CHB + hepatic steatosis patients who received different drugs in a short term.
Time Frame: 3 months
|
The common measurement includes serum biochemistry markers (ALT, AST, GGT, CRP, PT, APTT, AMA, UA, Chol, TG, TB, DB, ALP, fasting glucose, insulin, et al), virus markers (HBs-Ag, Hbe-Ag, anti-HBc-Ab, HBV genotype, HBV- DNA copy, YMDD variation, et al), Liver CT scan or ultrasound (steatosis degree and fibrosis).
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Fatty Liver
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Anti-Infective Agents
- Antiviral Agents
- Platelet Aggregation Inhibitors
- Antimetabolites
- Immunologic Factors
- Protective Agents
- Micronutrients
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Anti-Bacterial Agents
- Adjuvants, Immunologic
- Vitamins
- Antioxidants
- Antitubercular Agents
- Entecavir
- Vitamin E
- Essential 303 forte
Other Study ID Numbers
Other Study ID Numbers
- NCTZJU201001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.